Fosun Pharma and Neovii signed an agreement to exclusively sell and develop Grafalon (anti-human T cell rabbit immunoglobulin) in China
Shanghai, China and Rapperswil, Switzerland) Shanghai Fosun Pharma (Group) Co. (“Fosun Pharma”, stock code : 600196.SH; 02196.HK) announced that Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (“Fosun Pharmaceutical Industry”), a controlled subsidiary, signed an exclusive sales agency and development agreement with Switzerland ’s Neovii Pharmaceuticals AG (hereinafter referred to as “Neovii”). Fosun Pharma has been authorized by Neovii to exclusively sell and develop its immunosuppressant Grafalon ® (anti-human T cell rabbit immunoglobulin injection, hereinafter referred to as the "cooperative product") in China, Hong Kong, Macao and Taiwan.
According to the agreement, Fosun Pharma will pay Neovii sales agency royalties and payments based on milestones in the launch of cooperative products, and the two parties will settle based on the sales price and sales commission. In addition, Fosun Pharma can authorize its subsidiaries to commercialize cooperative varieties.
Grafalon ® (Anti-Human T Cell Rabbit Immunoglobulin, ATLG, also known as "ATG-FreseniusS" and "ATG-F"), developed by Neovii and approved in more than 50 countries to improve outcomes for transplant recipients , and in some countries for the treatment of aplastic anemia. Grafalon® has a solid clinical experience benefiting more than 250,000 patients and is a leader in many countries, changing the way that teams of transplant medical workers manage patient care and addressing a significant unmet need.
Mr. Wen Deyong, CEO of Fosun Pharma, said: "We are delighted to work with Neovii to advance the commercialization and development of Grafalon in China. Grafalon has excellent rejection prevention for solid organ transplant recipients, especially those with a high risk of rejection. In the future, we will leverage Fosun Pharma’s advantages in the fields of kidney and blood system diseases and other therapeutic fields to improve the availability of medicines for patients and benefit more Chinese patients.”
Neovii CEO Dr. Christian Loss said : "As a leading global pharmaceutical and healthcare industry group in China, Fosun Pharma is an ideal partner for the development and commercialization of Grafalon in China, Hong Kong, Macao and Taiwan. This cooperation will help Grafalon in China`s continued growth and drive the development of other disease areas such as autoimmune diseases. We look forward to working with Fosun Pharma to bring Grafalon to more Chinese patients in need."
About Fosun Pharma
Shanghai Fosun Pharma (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH, 02196.HK) was established in 1994. It is a global pharmaceutical and health industry group rooted in China and driven by innovation. The operating businesses include pharmaceuticals, medical devices, medical diagnosis, medical and health services, and cover the pharmaceutical business field through participation in Sinopharm Holdings.
Fosun Pharma is patient-centered and clinical needs-oriented, and enriches its innovative product pipeline through diversified and multi-level cooperation models such as independent research and development, cooperative development, licensing introduction, and deep incubation. Focusing on key disease areas such as tumor and immune regulation, metabolism and digestive system, and central nervous system, Fosun Pharma has built and formed technology platforms for small molecule innovative drugs, antibody drugs, and cell therapy, and actively explores RNA, gene therapy, ADC, Targeting cutting-edge technology fields such as protein degradation to enhance innovation capabilities.
Under the guidance of the "4IN" (Innovation, Internationalization, Intelligentization, and Integration) strategy, Fosun Pharma will adhere to the development model of "innovative transformation, integrated operation, and steady growth" and the belief in creating value for shareholders. Continuously strengthen independent research and development and external cooperation, enrich product pipelines, strengthen global layout, and improve operational efficiency. At the same time, actively promote the online and offline layout of the medical and health industry, and strive to become a first-class enterprise in the global medical and health market.
About Neovii
Headquartered in Switzerland, Neovii is a global, fast-growing, commercial-stage biopharmaceutical company with operations in more than 50 countries. For more than 30 years, Neovii has been dedicated to bringing new treatments to patients with diseases with serious unmet clinical needs. Neovii is a member of the Neopharm Group, which, through its affiliates, conducts research, development and commercialization of a wide range of products and value-added services in the three sectors of pharmaceuticals, medical and consumer healthcare, with revenues in excess of $500 million and a global network of more than 1,000 employees.